Standards—An Important Patent Portfolio Licensing Opportunity
Robert A. MyersFairfield Resources International, Inc., Senior Vice President, Darien, CT USA In the 1980s, Texas Instruments and, somewhat later, IBM showed that it is possible for a company with a strong patent portfolio to reap large added rents for their sunk R&D costs through patent assertion and licensing. Seeing this opportunity, enterprises and universities […]
Border Detention Of Patent Infringing Goods In The European Union
Christoph CordesEsche Schuemann Commichau, Attorney at Law, Hamburg, Germany Border detention proceedings are an important tool for safeguarding patent protection: On application of the right-holder customs authorities detain goods which are suspected to infringe intellectual property rights. After a short period of time, customs officials destroy the goods unless the importer objects which triggers court […]
Intellectual Property And Other Contractual Issues In Cooperative Research And Development Agreements (CRADAs): Part II
Matthew W. SagalAlliance Management Group, Senior Manager, Marblehead, MA, USAGene SlowinskiRutgers University, Director, Strategic Alliance Research, Newark, NJ, USAKenneth B. FreeseLos Alamos National Laboratories, Manager, Intellectual Asset StrategiesSteven FergusonOffice of Technology Transfer, National Institutes of Health, Deputy Director, Licensing and Entrepreneurship, Rockville, MD, USA This review of Cooperative Research and Development Agreements (CRADAs) is being […]
Shionogi/Purdue Strategic Discovery Alliance With Synchronicity And Serendipity—Case Study Of Open Innovation
Eiichi YamaguchiShionogi & Co., Ltd., Head of Licensing, General Manager, Osaka, Japan The utilization of open innovation (Chesbrough, 20041) for two companies will affect the long-term corporate strategies at both companies. Even prior to the term “open innovation,” Shionogi & Co., Ltd. licensed MS Contin® & OxyContin®, from Mundipharma K.K., the Japanese affiliate of Purdue […]
A Review Of The LES (USA & Canada) 2007/2008 BioPharmaceutical Royalty Rate And Deal Terms Survey
Steven RenwickPharmaVentures Ltd, Consultant, Oxford, UK James A. McCarthyCLP, EGEN, Inc., Senior Vice President, Corporate Development, Huntsville, AL, USA Intellectual property valuation in the healthcare sector is often achieved through a combination of discounted cash flow (DCF) and net present value (NPV) calculations, supported by benchmarking based on publicly available deal information. Published total deal […]
Recent U.S. Decisions And Developments Affecting Licensing – September 2009
Brian BrunsvoldFinnegan, Henderson, Farabow, Garrett & Dunner, LLP, Attorney, Washington, D.C., USA John C. PaulFinnegan, Henderson, Farabow, Garrett & Dunner, LLP, Attorney, Washington, D.C., USA ATTENDING U.S. TRADE SHOWS CAN SUBJECT A FOREIGN COMPANY TO THE JURISDICTION OF THE U.S. COURT AT THAT LOCATION To avoid an unfair result or undue burden on defendants, the […]
Negotiating Pharmaceutical Licensing Deal Structures: Confrontation or Common Ground?
Michael J. MartinMicroDose Therapeutx, Vice President, Licensing and Business Development, Monmouth Junction, NJ, USA Start your engines and look for the checkered flag! Lets’s face it, product and technology licensing negotiations between pharmaceutical and biotechnology companies are challenging, difficult and protracted. From initiating a transaction to ultimate contract, it can take more than a year, […]
Technology Transfer Between Academy And Industry – A Comparison Of The Situation In Germany And United Kingdom
Meital WernerMunich, Germany Heinz Goddar, PhDBoehmert & Boehmert, Patent Attorney, Munich, Germany The paper will explore the legal relationship between industry, academia and government in research collaboration and technology transfer in Germany in comparison to the UK and will raise the questions, to which extent the recent legal changes in Germany have actually improved the […]
Intellectual Property, File-Sharing and Privacy: The Challenge Is On The Internet
Luciano DaffarraLawyer, Daffarra d’Addio & Partners, Milano, Italy This article represents a synthetic work meant to help readers understand the main problems concerning the protection of intellectual works over the Internet. Far be it from exhausting all the aspects of this matter, nevertheless it aims to establish some “landmarks” that may possibly show some ways […]
The Valuation Of Drug Development Project – Part 1
Sangeeta PuranMayer Brown International, Senior Associate, London, UK Overview Earlier in March, 2009, the author completed a study examining the methods used to value drug development programmes. The study was conducted by interviewing individuals over a period of four months in the UK from a representative sample of twelve leading industry participants, including small biotech […]
